Browse Studies — Arctuva

Phase 2

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this st…

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)Pancreatic Enzyme Abnormality+1 more

Estimated

~$10 – $8,750

Aimmune Nestlé Health Science US R&D, LLCNCT07559175

Phase 2

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine p…

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)

Estimated

~$10 – $8,750

Anagram Therapeutics, Inc.NCT07450547

Phase 3

A Randomized Controlled Trial to Evaluate the Efficacy of Immobilized Lipase (RELiZORB) During Enteral Nutrition in Patients With Exocrine Pancreatic Insufficiency Secondary to Acute Pancreatitis

This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammatio…

Exocrine Pancreatic Insufficiency (EPI)Pancreatitis

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06691893